Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ONB$25.03-0.01(-0.02%)Old National Chairman and CEO Jim Ryan Named Chair-Elect of the American Bankers Association[2:07:00 PM ET]BCRD$5.530.00(0.00%)BlueOne Technologies Announces Enhance Global Remittance Platform[2:04:41 PM ET]CWK$12.13+0.22(+1.89%)Cushman & Wakefield Arranges $130 Million Sale of Seasons of Traverse Mountain in Lehi, Utah[2:01:00 PM ET]CTAS$213.37-12.56(-5.56%)Cintas Corporation Announces Quarterly Cash Dividend[2:00:00 PM ET]QNBC$46.40+0.40(+0.87%)QNB Corp. Reports Third Quarter 2026 Results[1:59:23 PM ET]CNXC$31.28-0.73(-2.28%)Concentrix Breaks the Language Barrier with Live Voice Translation[1:55:00 PM ET]CEG$257.87+5.39(+2.13%)Constellation Secures Conditional DOE Loan Commitment of up to $5 Billion to Expand Nuclear Output[1:35:00 PM ET]TXTM$0.01+0.00(+3.81%)Canouse Announces Unsatisfied Federal Judgment Against Protext Mobility, Inc. (OTC: TXTM)[1:35:00 PM ET]ARAI$0.11-0.00(-1.34%)Arrive AI Installs First Arrive Point(TM) Residential Unit[1:23:00 PM ET]

VTRS · NASDAQ

Viatris Inc.

$18.76 +0.46 (+2.54%)

Company overview

Viatris Inc. operates as a global healthcare company with four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). Its therapeutic areas include noncommunicable and infectious diseases, as well as biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology. Viatris also provides APIs for antibacterial, central nervous system, antihistamine/antiasthma, cardiovascular, antiviral, antidiabetic, antifungal, and proton pump inhibitor applications. The company supports patients through diagnostic clinics, educational seminars, and digital health tools.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$21.5B
Employees
32,000
Headquarters
Canonsburg, PA
Website
viatris.com
CEO
Scott Andrew Smith
Listed
March 17, 1980
P/E
-71.01
Dividend yield
2.94%

Company financials

Revenue
$14.6B
Gross profit
$5B
Operating income
$139M
EBITDA
$1.9B
Net income
-$296M
EPS
-$0.26
Total assets
$36.8B
Total debt
$14.3B
Gross margin
34.40%
Net margin
-2.04%
Earnings yield
-1.41%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

14.2515.4216.5917.7518.92
VTRS 1D NASDAQ O18.20H18.40L18.11C18.29+0.29 (+1.61%)Vol6.06M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
VTRSViatris Inc. Stock news Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report? Zacks Investment Research
VTRSViatris Inc. Stock news Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term Zacks Investment Research
VTRSViatris Inc. Press release Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI®... PR Newswire
VTRSViatris Inc. Legal Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX Business Wire
VTRSViatris Inc. Stock news 2 Stocks Drawing Bearish Options Activity Today Schaeffers Research
VTRSViatris Inc. Stock news Viatris to Buy Pacira BioSciences for $1.65 Billion WSJ
VTRSViatris Inc. Press release Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies PRNewsWire
VTRSViatris Inc. Stock news VTRS vs. AVTR: Which Stock Is the Better Value Option? Zacks Investment Research
VTRSViatris Inc. Stock news Should Value Investors Buy Viatris (VTRS) Stock? Zacks Investment Research
VTRSViatris Inc. Stock news Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? Zacks Investment Research
VTRSViatris Inc. Press release Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026 PRNewsWire
VTRSViatris Inc. Stock news Why Viatris (VTRS) is a Top Value Stock for the Long-Term Zacks Investment Research
VTRSViatris Inc. Stock news Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year GuruFocus
VTRSViatris Inc. Press release Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year PR Newswire
VTRSViatris Inc. Stock news Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields Benzinga
VTRSViatris Inc. Press release Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome PR Newswire
VTRSViatris Inc. Stock news Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive Seeking Alpha
VTRSViatris Inc. Stock news Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? Zacks Investment Research
VTRSViatris Inc. Stock news Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris Proactive Investors
VTRSViatris Inc. Stock news Here's Why Viatris (VTRS) is a Strong Value Stock Zacks Investment Research
See more
FAQ

Questions about Viatris Inc.

What does Viatris Inc. do?
Viatris Inc. operates as a global healthcare company with four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). Its therapeutic areas include noncommunicable and infectious diseases, as well as biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology. Viatris also provides APIs for antibacterial, central nervous system, antihistamine/antiasthma, cardiovascular, antiviral, antidiabetic, antifungal, and proton pump inhibitor applications. The company supports patients through diagnostic clinics, educational seminars, and digital health tools.
What is VTRS's market cap?
Viatris Inc. (VTRS) is a listed stock with a live quote. The latest market cap on this page is $21.5B.
Where is Viatris Inc. headquartered?
Viatris Inc. is headquartered in Canonsburg, PA.
How do I get VTRS news from the API?
Call GET /v1/news?tickers=VTRS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does VTRS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VTRS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the VTRS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs